Chugai Pharmaceutical (OTCMKTS:CHGCY) versus China SXT Pharmaceuticals (NASDAQ:SXTC) Head-To-Head Comparison

China SXT Pharmaceuticals (NASDAQ:SXTC) and Chugai Pharmaceutical (OTCMKTS:CHGCY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Valuation & Earnings

This table compares China SXT Pharmaceuticals and Chugai Pharmaceutical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.74 million	1.66	-$3.30 million	N/A	N/A
Chugai Pharmaceutical	$8.41 billion	10.98	$2.90 billion	$0.87	32.25

Chugai Pharmaceutical has higher revenue and earnings than China SXT Pharmaceuticals.

Volatility and Risk

China SXT Pharmaceuticals has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Chugai Pharmaceutical has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.

Insider and Institutional Ownership

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Chugai Pharmaceutical shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares China SXT Pharmaceuticals and Chugai Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Chugai Pharmaceutical	34.47%	22.22%	19.46%

Analyst Ratings

This is a summary of recent ratings for China SXT Pharmaceuticals and Chugai Pharmaceutical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1	0	0	0	1.00
Chugai Pharmaceutical	0	0	0	1	4.00

Summary

Chugai Pharmaceutical beats China SXT Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.